ClinicalTrials.gg
CompletedNCT03560466Updated Nov 21, 2025Results posted

Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)

A Phase 3 interventional study of Dupilumab (SAR231893/REGN668) and Asthma controller therapies (incl. prednisone/prednisolone) in Asthma, sponsored by Sanofi. Completed at 81 sites in 18 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Not applicable
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
8th of 31
378 · median 120
Started
2018
with 1 other
Phase 3
11 of 31
2 open now
Registered
9th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 3, and was the 9th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

  • To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study.
  • To evaluate the efficacy of dupilumab in children of 6 to \<12 years of age with uncontrolled persistent asthma in the Japan sub-study.

Secondary Objectives:

  • To evaluate the long-term efficacy of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study.
  • To evaluate dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study with regard to:

    • Systemic exposure.
    • Anti-drug antibodies (ADAs).
    • Biomarkers.
  • To evaluate the safety and tolerability of dupilumab in pediatric patients with asthma in the Japan sub-study
  • To evaluate dupilumab in pediatric patients with asthma in the Japan substudy with regard to:

    • Systemic exposure,
    • Anti-drug antibodies (ADAs),
    • Biomarkers
Read the detailed description

Study duration per participant is approximatively 64 weeks including a 52 weeks treatment period and 12 weeks post treatment follow-up.

Japan substudy:

Study duration per participant is approximately 68 weeks including 3-5 weeks screening period, 52 weeks treatment period and 12 weeks post treatment follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients with asthma who completed the treatment in a dupilumab asthma trial (EFC14153).
  • Signed written /assent. Specific for Brazil: EFC14153 patients from Brazil, who prematurely discontinued Medicinal Product (IMP) to receive Yellow Fever vaccine (a ) during Yellow Fever outbreak, are allowed to be enrolled in LTS14424 after completing the required procedures in EFC14153 (completion of remaining visits and procedures until end of treatment (EOT) V28, considered as V1 for LTS14424).

Patients who are not able to complete their treatment in Study EFC14153 due to the COVID-19 pandemic will be allowed to enroll into Study LTS14424. Patients who enroll in LTS14424 after completing the EFC14153 EOS visit should have eligibility for LTS14424 reevaluated including background medication check and laboratory assessments (including complete blood count [CBC] with differential and basic chemistry) within 1 month prior to LTS14424 Visit 1.

For Japan sub-study

  • Signed written inform consent/assent
  • Children 6 to \<12 years of age, with a physician diagnosis of persistent asthma for ≥12 months prior to screening
  • Blood eosinophil count ≥150 cells/μL or fractional exhaled nitric oxide (FeNO) ≥20 parts per billion (ppb) at screening visit (Visit 0).

Exclusion criteria

Exclusion criteria:

  • Any chronic lung disease other than asthma (eg, cystic fibrosis, bronchopulmonary dysplasia) which may impair lung function.
  • Inability to follow the procedures of the study/noncompliance (eg, due to language problems or psychological disorders).
  • Patients receiving concomitant treatment or required a new concomitant treatment prohibited in the study.
  • Patients or his/her parent(s)/caregiver(s)/legal guardian(s) is related to the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff thereof directly involved in the conduct of the study.
  • Patients who experienced any reactions to dupilumab in a previous dupilumab study, which, in the opinion of the Investigator, could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient.
  • Any abnormalities or adverse events at screening (last treatment visit in the study EFC14153 will be the screening visit) that per Investigator judgment would adversely affect patient's participation in this study or would require permanent IMP discontinuation.
  • For female patients who have commenced menstruating at any time during the study and are either:
  • Found to have a positive urine pregnancy test, or
  • Sexually active, not using an established acceptable method.
  • Planned live, attenuated vaccinations during the study.
  • Patients with active disease or patients using therapy for autoimmune disease (eg, juvenile idiopathic arthritis, inflammatory bowel disease, systemic lupus erythematosus) at enrollment.

For Japan sub-study:

  • Any chronic lung disease other than asthma (eg, cystic fibrosis, bronchopulmonary dysplasia) which may impair lung function.
  • Inability to follow the procedures of the study/noncompliance (eg, due to language problems or psychological disorders).
  • Patients receiving concomitant treatment or required a new concomitant treatment prohibited in the study at the screening and enrollment visits.
  • Patients who previously have been treated with dupilumab
  • Diagnosed with active parasitic infection (helminthes); suspected or high risk of parasitic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before randomization
  • Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), despite infection resolution; or unusually frequent, recurrent, or prolonged infections, per Investigator's judgment.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
378 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks

    Drug: Dupilumab (SAR231893/REGN668) · Drug: Asthma controller therapies (incl. prednisone/prednisolone) · Drug: Asthma reliever therapies

Interventions

  • DrugDupilumab (SAR231893/REGN668)

    Drug page: Dupilumab

    Pharmaceutical form: solution for injection Route of administration: subcutaneous (sc)

  • DrugAsthma controller therapies (incl. prednisone/prednisolone)

    Pharmaceutical form: powder, or solution, or pill Route of administration: inhaled, oral or parenteral

  • DrugAsthma reliever therapies

    Pharmaceutical form: powder or solution Route of administration: inhaled

06

What researchers measure

Primary outcomes

  1. Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.

    Time frame: From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks

  2. Japan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline was defined as the last available measurement prior to the first study treatment dose if the participant was treated, or the last available value up to enrollment if the participant was not exposed to study treatment in the current study.

    Time frame: Baseline (Day 1) to Week 12

Secondary outcomes

  1. Japan Sub-study: Number of Participants With Any Treatment-Emergent Adverse Events

    An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.

    Time frame: From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks

  2. Annualized Rate of Severe Asthma Exacerbation Events During the 52-Week Treatment Period

    A severe exacerbation event during study was defined as a deterioration of asthma requiring use of systemic corticosteroid (SCS) for ≥3 days or hospitalization/emergency room visit because of asthma, requiring SCS. Annualized severe exacerbation event rate was defined as total number of events that occurred during 52-week treatment period divided by total number of participant-years followed in 52-week treatment period.

    Time frame: Up to Week 52

  3. Change From Baseline in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second Over Time

    FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64

  4. Change From Baseline in Absolute Forced Expiratory Volume in 1 Second Over Time

    FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64

  5. Change From Baseline in Forced Vital Capacity (FVC) Over Time

    FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline (main study):original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64

  6. Change From Baseline in Forced Expiratory Flow [FEF] 25% to 75% Over Time

    FEF was defined as amount of air which can be forcibly exhaled from lungs in first second of forced exhalation. FEF 25-75% was the mean FEF between 25% and 75% of FVC. FVC was defined as volume of air that could be forcibly blown out after full inspiration in upright position. Spirometry was performed after wash out period of bronchodilators. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64

  7. Main Study: Change From Baseline in Percent Predicted Forced Vital Capacity Over Time

    FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline was defined as the original baseline of parent study EFC14153.

    Time frame: Baseline (Day 1) and Weeks 2, 8, 12, 24, 52 and 64

  8. Japan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-Question Version (ACQ-7-IA) Over Time

    ACQ-7-IA had 7 questions with first 5 items of ACQ-7 addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma, wheeze; 2 questions on short-acting bronchodilator use and predicted bronchodilator use of FEV1. Participants/parents/guardians recalled child's previous week asthma and responded to questions on 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-7-IA score was the mean of 7 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) and Weeks 2, 4, 8, 12, 24, 36, 52 and 64

  9. Japan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-Question Version (ACQ-5-IA) Over Time

    The ACQ-5-IA had 5 questions addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze. Participants/parents/guardians recalled the child's previous week asthma and responded to symptom and bronchodilator use questions on a 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-5-IA score was the mean of 5 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) and Weeks 2, 4, 8, 12, 24, 36, 52 and 64

  10. Serum Concentrations of Dupilumab

    Blood samples were collected at the specified timepoints for determination of functional dupilumab concentration in serum.

    Time frame: Weeks 12, 24, 52 and 64

  11. Number of Participants With Anti-Drug Antibodies (ADAs) Against Dupilumab

    ADA positive was defined as either treatment-boosted or treatment-emergent response in the ADA assay. Treatment-boosted response was defined as a positive response in the ADA assay post first dose in the current study that was greater than or equal to 4-fold of the baseline titer levels, when baseline results were positive. Treatment-emergent response was defined as a positive response in the ADA assay post first dose in the current study, when baseline results were negative or missing. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: From first dose of study treatment (Day 1) to Week 64

  12. Main Study: Percent Change From Baseline in Blood Eosinophil Count at Week 64

    Blood samples were collected at specified timepoints to assess percent change from baseline in eosinophil count. Baseline was defined as the original baseline of parent study EFC14153.

    Time frame: Baseline (Day 1) to Week 64

  13. Percent Change From Baseline in Total Immunoglobulin (Ig) E in Serum at Week 64

    Blood samples were collected at specified timepoints to assess percent change from baseline in total IgE in serum. Baseline (main study): the original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

    Time frame: Baseline (Day 1) to Week 64

  14. Japan Sub-study: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 64

    FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second. FeNO assessment was conducted prior to spirometry and following a fast of ≥1 hour. Baseline was defined as the last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in the current study.

    Time frame: Baseline (Day 1) to Week 64

07

Results

Posted Nov 21, 2025

Participant flow

The main study was conducted at 70 centers in 17 countries, and the sub-study was conducted at 11 centers in Japan. 365 participants who rolled over from parent study EFC14153 (NCT02948959) were enrolled in the main study and 13 participants (not included in parent study EFC14153) were enrolled in Japan sub-study.

Participant flow — Overall Study
MilestoneMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Started12524013
Completed11822812
Not completed7121
Withdrew: Adverse event120
Withdrew: Poor compliance to protocol020
Withdrew: Other681

Outcome measures

PrimaryMain Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.

Time frame:
From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)
ParticipantsMain Study: Placebo-DupilumabMain Study: Dupilumab-Dupilumab
Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)85147
PrimaryJapan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)

FEV1 was the volume of air (in liters) exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline was defined as the last available measurement prior to the first study treatment dose if the participant was treated, or the last available value up to enrollment if the participant was not exposed to study treatment in the current study.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · percent predicted FEV1
Japan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)
percent predicted FEV1Japan Sub-study: Dupilumab
Japan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)7.08 ± 6.78
SecondaryJapan Sub-study: Number of Participants With Any Treatment-Emergent Adverse Events

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. TEAEs were AEs that developed or worsened or became serious during the TEAE period.

Time frame:
From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks
Reported as:
Count of participants · Participants
Japan Sub-study: Number of Participants With Any Treatment-Emergent Adverse Events
ParticipantsJapan Sub-study: Dupilumab
Japan Sub-study: Number of Participants With Any Treatment-Emergent Adverse Events13
SecondaryAnnualized Rate of Severe Asthma Exacerbation Events During the 52-Week Treatment Period

A severe exacerbation event during study was defined as a deterioration of asthma requiring use of systemic corticosteroid (SCS) for ≥3 days or hospitalization/emergency room visit because of asthma, requiring SCS. Annualized severe exacerbation event rate was defined as total number of events that occurred during 52-week treatment period divided by total number of participant-years followed in 52-week treatment period.

Time frame:
Up to Week 52
Reported as:
Number · exacerbations per participant-years
Annualized Rate of Severe Asthma Exacerbation Events During the 52-Week Treatment Period
exacerbations per participant-yearsMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Annualized Rate of Severe Asthma Exacerbation Events During the 52-Week Treatment Period0.1140.1200.462
SecondaryChange From Baseline in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second Over Time

FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Reported as:
Mean · percent predicted FEV1
Change From Baseline in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second Over Time
percent predicted FEV1Main Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Week 28.06 ± 15.7111.03 ± 18.747.50 ± 9.29
Week 4——7.00 ± 7.12
Week 87.93 ± 14.8812.47 ± 18.606.31 ± 8.97
Week 128.31 ± 14.7010.95 ± 17.337.08 ± 6.78
Week 248.37 ± 15.4811.23 ± 18.244.08 ± 8.75
Week 528.81 ± 16.1812.19 ± 17.886.73 ± 8.09
Week 647.98 ± 17.1410.67 ± 17.191.17 ± 8.03
SecondaryChange From Baseline in Absolute Forced Expiratory Volume in 1 Second Over Time

FEV1 was volume of air (in liters) exhaled from the lungs in first second of a forced expiration as measured by spirometer. Spirometry was performed after a wash out period of bronchodilators according to their action duration. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Reported as:
Mean · liter
Change From Baseline in Absolute Forced Expiratory Volume in 1 Second Over Time
literMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Week 20.36 ± 0.320.42 ± 0.380.13 ± 0.15
Week 4——0.13 ± 0.13
Week 80.38 ± 0.320.47 ± 0.390.12 ± 0.15
Week 120.41 ± 0.310.45 ± 0.360.17 ± 0.13
Week 240.46 ± 0.350.51 ± 0.390.15 ± 0.15
Week 520.62 ± 0.410.66 ± 0.410.34 ± 0.21
Week 640.66 ± 0.450.70 ± 0.440.25 ± 0.14
SecondaryChange From Baseline in Forced Vital Capacity (FVC) Over Time

FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline (main study):original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Reported as:
Mean · liter
Change From Baseline in Forced Vital Capacity (FVC) Over Time
literMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Week 20.35 ± 0.290.38 ± 0.380.11 ± 0.15
Week 4——0.09 ± 0.12
Week 80.37 ± 0.300.45 ± 0.420.11 ± 0.14
Week 120.40 ± 0.300.43 ± 0.390.12 ± 0.11
Week 240.47 ± 0.360.50 ± 0.400.17 ± 0.15
Week 520.68 ± 0.420.70 ± 0.450.36 ± 0.22
Week 640.74 ± 0.490.75 ± 0.480.41 ± 0.24
SecondaryChange From Baseline in Forced Expiratory Flow [FEF] 25% to 75% Over Time

FEF was defined as amount of air which can be forcibly exhaled from lungs in first second of forced exhalation. FEF 25-75% was the mean FEF between 25% and 75% of FVC. FVC was defined as volume of air that could be forcibly blown out after full inspiration in upright position. Spirometry was performed after wash out period of bronchodilators. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) and Weeks 2, 4 (Japan sub-study), 8, 12, 24, 52 and 64
Reported as:
Mean · liter per second
Change From Baseline in Forced Expiratory Flow [FEF] 25% to 75% Over Time
liter per secondMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Week 20.49 ± 0.630.58 ± 0.660.21 ± 0.26
Week 4——0.25 ± 0.23
Week 80.48 ± 0.600.62 ± 0.630.15 ± 0.30
Week 120.54 ± 0.600.59 ± 0.610.29 ± 0.31
Week 240.58 ± 0.680.66 ± 0.650.15 ± 0.37
Week 520.73 ± 0.750.77 ± 0.670.40 ± 0.46
Week 640.77 ± 0.780.79 ± 0.700.11 ± 0.34
SecondaryMain Study: Change From Baseline in Percent Predicted Forced Vital Capacity Over Time

FVC was defined as volume of air (in liters) that could be forcibly blown out after full inspiration in upright position as measured by spirometer. Spirometry was performed after wash out period of bronchodilators according to their action duration. Baseline was defined as the original baseline of parent study EFC14153.

Time frame:
Baseline (Day 1) and Weeks 2, 8, 12, 24, 52 and 64
Reported as:
Mean · percent predicted FVC
Main Study: Change From Baseline in Percent Predicted Forced Vital Capacity Over Time
percent predicted FVCMain Study: Placebo-DupilumabMain Study: Dupilumab-Dupilumab
Week 22.98 ± 12.915.02 ± 16.33
Week 82.88 ± 12.176.64 ± 17.42
Week 123.23 ± 12.495.03 ± 16.45
Week 243.19 ± 13.355.28 ± 16.20
Week 523.74 ± 13.106.43 ± 16.40
Week 643.13 ± 15.144.83 ± 16.09
SecondaryJapan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-Question Version (ACQ-7-IA) Over Time

ACQ-7-IA had 7 questions with first 5 items of ACQ-7 addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma, wheeze; 2 questions on short-acting bronchodilator use and predicted bronchodilator use of FEV1. Participants/parents/guardians recalled child's previous week asthma and responded to questions on 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-7-IA score was the mean of 7 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher scores indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) and Weeks 2, 4, 8, 12, 24, 36, 52 and 64
Reported as:
Mean · score on a scale
Japan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-Question Version (ACQ-7-IA) Over Time
score on a scaleJapan Sub-study: Dupilumab
Week 2-0.65 ± 0.64
Week 4-0.68 ± 0.75
Week 8-0.84 ± 0.59
Week 12-1.03 ± 0.66
Week 24-0.96 ± 0.61
Week 36-1.01 ± 0.47
Week 52-1.21 ± 0.37
Week 64-0.99 ± 0.52
SecondaryJapan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-Question Version (ACQ-5-IA) Over Time

The ACQ-5-IA had 5 questions addressing most common asthma symptoms: frequency in past week awoken by asthma during night, severity of asthma symptoms in morning, limitation of daily activities due to asthma, shortness of breath due to asthma and wheeze. Participants/parents/guardians recalled the child's previous week asthma and responded to symptom and bronchodilator use questions on a 7-point scale: 0=no impairment, 6=maximum impairment. Global ACQ-5-IA score was the mean of 5 questions, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control. Baseline: last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) and Weeks 2, 4, 8, 12, 24, 36, 52 and 64
Reported as:
Mean · score on a scale
Japan Sub-study: Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-Question Version (ACQ-5-IA) Over Time
score on a scaleJapan Sub-study: Dupilumab
Week 2-0.68 ± 0.87
Week 4-0.75 ± 1.06
Week 8-0.92 ± 0.82
Week 12-1.20 ± 0.84
Week 24-1.15 ± 0.68
Week 36-1.25 ± 0.54
Week 52-1.49 ± 0.54
Week 64-1.28 ± 0.59
SecondarySerum Concentrations of Dupilumab

Blood samples were collected at the specified timepoints for determination of functional dupilumab concentration in serum.

Time frame:
Weeks 12, 24, 52 and 64
Reported as:
Mean · nanogram per milliliter
Serum Concentrations of Dupilumab
nanogram per milliliterMain Study: Dupilumab 100 mg q2wMain Study: Dupilumab 200 mg q2wMain Study: Dupilumab 300 mg q4wJapan Sub-study: Dupilumab 100 mg q2wJapan Sub-study: Dupilumab 200 mg q2wJapan Sub-study: Dupilumab 300 mg q4w
Week 1260740.38 ± 23885.7780450.15 ± 39865.2479600.00 ± 25509.8438600.00 ± 20850.1879128.57 ± 24513.3153066.67 ± 18569.96
Week 2464201.03 ± 22890.0281849.66 ± 42824.9380675.00 ± 26921.2741300.00 ± 22138.6598316.67 ± 18066.8155166.67 ± 14558.96
Week 5252808.85 ± 21526.0571910.74 ± 42290.5481289.94 ± 31957.0741000.00 ± 23157.9491128.57 ± 28739.3359300.00 ± 18107.46
Week 641884.04 ± 9763.013391.86 ± 16196.36184.69 ± 582.7539.00 ± 0.0039.00 ± 0.0039.00 ± 0.00
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) Against Dupilumab

ADA positive was defined as either treatment-boosted or treatment-emergent response in the ADA assay. Treatment-boosted response was defined as a positive response in the ADA assay post first dose in the current study that was greater than or equal to 4-fold of the baseline titer levels, when baseline results were positive. Treatment-emergent response was defined as a positive response in the ADA assay post first dose in the current study, when baseline results were negative or missing. Baseline (main study): original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
From first dose of study treatment (Day 1) to Week 64
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) Against Dupilumab
ParticipantsMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Treatment-boosted ADA Response10—
Treatment-emergent ADA Response1072
SecondaryMain Study: Percent Change From Baseline in Blood Eosinophil Count at Week 64

Blood samples were collected at specified timepoints to assess percent change from baseline in eosinophil count. Baseline was defined as the original baseline of parent study EFC14153.

Time frame:
Baseline (Day 1) to Week 64
Reported as:
Mean · percent change
Main Study: Percent Change From Baseline in Blood Eosinophil Count at Week 64
percent changeMain Study: Placebo-DupilumabMain Study: Dupilumab-Dupilumab
Main Study: Percent Change From Baseline in Blood Eosinophil Count at Week 6434.528 ± 207.06729.769 ± 323.837
SecondaryPercent Change From Baseline in Total Immunoglobulin (Ig) E in Serum at Week 64

Blood samples were collected at specified timepoints to assess percent change from baseline in total IgE in serum. Baseline (main study): the original baseline of parent study EFC14153. Baseline (sub-study): last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in current study.

Time frame:
Baseline (Day 1) to Week 64
Reported as:
Median · percent change
Percent Change From Baseline in Total Immunoglobulin (Ig) E in Serum at Week 64
percent changeMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
Percent Change From Baseline in Total Immunoglobulin (Ig) E in Serum at Week 64-76.9 ± -85.2-86.8 ± -91.4-75.0 ± -81.1
SecondaryJapan Sub-study: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 64

FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 milliliter per second. FeNO assessment was conducted prior to spirometry and following a fast of ≥1 hour. Baseline was defined as the last available measurement prior to first study treatment dose if participant was treated, or last available value up to enrollment if participant was not exposed to study treatment in the current study.

Time frame:
Baseline (Day 1) to Week 64
Reported as:
Mean · parts per billion
Japan Sub-study: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 64
parts per billionJapan Sub-study: Dupilumab
Japan Sub-study: Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 64-8.3 ± 27.5

Adverse events

Collected over AEs: From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks for main study and sub-study each. Deaths: From first dose of study treatment (Day 1) up to end of follow-up, approximately 353 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Placebo-Dupilumab0/125 (0%)1/125 (0.8%)63/125 (50.4%)
Main Study: Dupilumab-Dupilumab0/240 (0%)6/240 (2.5%)108/240 (45%)
Japan Sub-study: Dupilumab0/13 (0%)4/13 (30.8%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
AsthmaRespiratory, thoracic and mediastinal disorders0/1250/2402/13
BronchitisInfections and infestations0/1250/2401/13
InfluenzaInfections and infestations0/1250/2401/13
PneumoniaInfections and infestations1/1250/2400/13
ConstipationGastrointestinal disorders0/1251/2400/13
Complicated AppendicitisInfections and infestations0/1251/2400/13
Pulmonary TuberculosisInfections and infestations0/1251/2400/13
Upper Respiratory Tract InfectionInfections and infestations0/1251/2400/13
Radius FractureInjury, poisoning and procedural complications0/1251/2400/13
AtelectasisRespiratory, thoracic and mediastinal disorders0/1251/2400/13
Most frequent other events
Showing 10 of 39
Most frequent other events
EventMain Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: Dupilumab
PyrexiaGeneral disorders3/1255/2406/13
InfluenzaInfections and infestations7/12513/2405/13
NasopharyngitisInfections and infestations12/12521/2405/13
PharyngitisInfections and infestations12/12515/2405/13
BronchitisInfections and infestations5/1257/2403/13
DiarrhoeaGastrointestinal disorders7/12510/2402/13
Covid-19Infections and infestations1/1253/2402/13
Upper Respiratory Tract InfectionInfections and infestations5/12519/2402/13
ArthralgiaMusculoskeletal and connective tissue disorders1/1252/2402/13
Tension HeadacheNervous system disorders0/1250/2402/13

Baseline characteristics

Main study: safety population included all participants exposed to at least 1 dose or part of a dose of the study treatment during current study regardless of the amount of treatment administered. Sub-study: enrolled population included all participants who signed the informed consent/assent and had a treatment kit number allocated and recorded in the interactive voice response system/interactive web response system database, regardless of whether the treatment kit was received or not.

Age, Continuous
Age, Continuous(years)Main Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: DupilumabTotal
Mean9.9 ± 1.69.9 ± 1.79.69 ± 1.119.89 ± 1.62
Sex: Female, Male
Sex: Female, Male(Participants)Main Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: DupilumabTotal
Female46854135
Male791559243
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Main Study: Placebo-DupilumabMain Study: Dupilumab-DupilumabJapan Sub-study: DupilumabTotal
Caucasian/White1112150326
Black/of African Descent69015
Asian011314
American Indian or Alaska Native0101
Other814022
08

Study locations

81 sites
  • Arizona Allergy and Immunology Research- Site Number : 8400002
    Gilbert, Arizona 85234, United States
  • Asthma and Airway Disease Research Center Site Number : 8400012
    Tucson, Arizona 85274, United States
  • Peninsula Research Associates Site Number : 8400001
    Rolling Hills Estates, California 90274, United States
  • Division of Pulmonary Medicine and Allergy Medicine- Site Number : 8400006
    St Louis, Missouri 63110-1077, United States
  • Somnos Clinical Research Site Number : 8400022
    Lincoln, Nebraska 68505, United States
  • Northwell Health- Site Number : 8400023
    Great Neck, New York 11021, United States
  • Columbia University Medical Center- Site Number : 8400013
    New York, New York 10032, United States
  • Rochester Regional Health- Site Number : 8400007
    Rochester, New York 14607, United States
  • Immunocarolina LLC Site Number : 8400004
    Charlotte, North Carolina 28277, United States
  • Cincinnati Children's Hospital Medical Center Site Number : 8400008
    Cincinnati, Ohio 45229, United States
  • OK Clinical Research, LLC- Site Number : 8400024
    Edmond, Oklahoma 73034, United States
  • Allergy & Asthma Research Center- Site Number : 8400003
    San Antonio, Texas 78229, United States
  • Investigational Site Number : 0320002
    CABA, Buenos Aires C1122AAK, Argentina
  • Investigational Site Number : 0320001
    CABA, Buenos Aires C1414AIF, Argentina
  • Investigational Site Number : 0320004
    Vicente Lopez, Buenos Aires F.D. B1602DQD, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number : 0320006
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0360005
    North Adelaide, South Australia 5006, Australia
  • Irmandade da Santa Casa de Misericordia de Porto Alegre- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital Sao Lucas da PUCRS- Site Number : 0760007
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Unidade Ambulatorial de Pesquisa Clinica I - NGP - UNIFESP- Site Number : 0760002
    São Paulo, São Paulo 04037-002, Brazil
  • Instituto da Criança of Hospital das Clínicas de São Paulo- Site Number : 0760004
    São Paulo, São Paulo 05403-000, Brazil
  • Clinica de Alergia Martti Antila Site Number : 0760006
    Sorocaba, São Paulo 18040-425, Brazil
  • Investigational Site Number : 1240003
    Québec, G1V 4W2, Canada
  • Investigational Site Number : 1520001
    Valdivia, Los Ríos Region 5090145, Chile
  • Investigational Site Number : 1520005
    Santiago, Reg Metropolitana de Santiago 838-0418, Chile
  • Investigational Site Number : 1520009
    Santiago, Reg Metropolitana de Santiago 8380453, Chile
  • Investigational Site Number : 1520007
    Viña del Mar, Valparaiso 2520024, Chile
  • Investigational Site Number : 1520002
    Viña del Mar, Valparaiso 2520594, Chile
  • Investigational Site Number : 1700004
    Antioquia, 050010, Colombia
  • Investigational Site Number : 1700002
    Cali, 760043, Colombia
  • Investigational Site Number : 3480006
    Budapest, 1089, Hungary
  • Investigational Site Number : 3480002
    Gyula, 5700, Hungary
  • Investigational Site Number : 3480012
    Mezőkövesd, 3400, Hungary
  • Investigational Site Number : 3480001
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number : 3480008
    Szigetvár, 7900, Hungary
  • Investigational Site Number : 3480003
    Töröbálint, 2045, Hungary
  • Investigational Site Number : 3480007
    Zalaegerszeg, 8900, Hungary
  • Investigational Site Number : 3800003
    Florence, 50139, Italy
  • Investigational Site Number : 3800004
    Padova, 35128, Italy
  • Investigational Site Number : 3800005
    Roma, 00146, Italy
  • Investigational Site Number : 3920013
    Chiba, Chiba 266-0007, Japan
  • Investigational Site Number : 3920016
    Chuo-ku, Chiba 260-0001, Japan
  • Investigational Site Number : 3920005
    Yotsukaido-shi, Chiba 284-0003, Japan
  • Investigational Site Number : 3920015
    Fukuoka, Fukuoka 811-1394, Japan
  • Investigational Site Number : 3920011
    Fukuoka, Fukuoka 813-0017, Japan
  • Investigational Site Number : 3920008
    Shibukawa, Gunma 377-8577, Japan
  • Investigational Site Number : 3920014
    Onomichi-shi, Hiroshima 722-8508, Japan
  • Investigational Site Number : 3920003
    Sapporo, Hokkaido 064-0821, Japan
  • Investigational Site Number : 3920012
    Tsu, Mie-ken 514-0125, Japan
  • Investigational Site Number : 3920010
    Ureshino-shi, Saga-ken 843-0393, Japan
  • Investigational Site Number : 3920009
    Habikino-Shi, 583-0872, Japan
  • Investigational Site Number : 4400005
    Šiauliai, LT-76231, Lithuania
  • Investigational Site Number : 4400003
    Utena, LT-28151, Lithuania
  • Investigational Site Number : 4400001
    Vilnius, LT-08406, Lithuania
  • Investigational Site Number : 4400004
    Vilnius, LT-09108, Lithuania
  • Investigational Site Number : 4840006
    Chihuahua City, 31000, Mexico
  • Investigational Site Number : 4840004
    Chihuahua City, 31200, Mexico
  • Investigational Site Number : 4840003
    Durango, Durango, 34080, Mexico
  • Investigational Site Number : 4840001
    Monterrey, Nuevo León, 64460, Mexico
  • Investigational Site Number : 4840002
    Veracruz, 91910, Mexico
  • Investigational Site Number : 6160002
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Investigational Site Number : 6160001
    Lodz, Lódzkie 90-329, Poland
  • Investigational Site Number : 6430004
    Perm, 614066, Russia
  • Investigational Site Number : 6430002
    Saint Petersburg, 193312, Russia
  • Investigational Site Number : 6430001
    Saint Petersburg, 194100, Russia
  • Investigational Site Number : 6430003
    Saint Petersburg, 196158, Russia
  • Investigational Site Number : 6430005
    Saint Petersburg, 197101, Russia
  • Investigational Site Number : 7100001
    Cape Town, 7700, South Africa
  • Investigational Site Number : 7240001
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7920005
    Adana, 01339, Turkey (Türkiye)
  • Investigational Site Number : 7920001
    Ankara, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    Istanbul, Turkey (Türkiye)
  • Investigational Site Number : 7920004
    Istanbul, Turkey (Türkiye)
  • Investigational Site Number : 8040007
    Chernivtsi, 58023, Ukraine
  • Investigational Site Number : 8040004
    Dnipro, 49101, Ukraine
  • Investigational Site Number : 8040005
    Kharkiv, 61093, Ukraine
  • Investigational Site Number : 8040008
    Kryvyi Rig, 50082, Ukraine
  • Investigational Site Number : 8040001
    Kyiv, 03115, Ukraine
  • Investigational Site Number : 8040002
    Zaporizhzhya, 69063, Ukraine
  • Investigational Site Number : 8040003
    Zaporizhzhya, 69076, Ukraine
09

References and documents

Publications

  • Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Guilbert TW, Jackson DJ, Staudinger HW, Laws E, Mannent LP, Akinlade B, Maloney J, Tawo K, Khokhar FA, Li N, Hardin M, Abdulai RM, Lederer DJ, Robinson LB; Liberty Asthma EXCURSION Investigators. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2024 Jan;12(1):45-54. doi: 10.1016/S2213-2600(23)00303-X. Epub 2023 Nov 10. PubMed 37956679 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Apr 2025, 81 months.

Results were first posted in Nov 2025, 7 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 81 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2018
First posted
Jun 18, 2018
StartActual
Jun 21, 2018
Primary completionActual
Apr 1, 2025
CompletionActual
Apr 1, 2025
Results first posted
Nov 21, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03560466
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 18, 2018
Start date
Jun 21, 2018
Primary completion
Apr 1, 2025
Completion
Apr 1, 2025
Results posted
Nov 21, 2025
Last update
Nov 21, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion